MapLight Therapeutics

MapLight Therapeutics

Biotechnology
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.

$442.9M

Market Cap • 10/23/2026

2018

(8 years)

Founded

2025

(1 year ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,3

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

6,3

EPS

—

Market Cap

Market Cap

442,9M

EV

140,2M

EV/Revenue

0

EV/EBITDA

-0,6

EV/EBIT

-0,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-60,8%

Total Yield

-60,8%

Payout

0%

Retained Earnings

-481,4M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

77,4%

Capex/OCF

-0,3%

SBC/OCF

—

% PPE

0,7%

% Goodwill

0%

ROE

—

ROIC

—

Leverage

N.D./EBITDA

1,2

Debt/Equity

0%

Current Ratio

16,5

Quick Ratio

15,8

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium